Dentists in Rumford, RI Accepting Medicare
3 Dentists found. Showing 1 - 3
 Dr. John O. Eastman, DDS Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 225 Newman Ave, Rumford, RI 02916 Phone: 401-438-5577 Fax: 401-438-5577 |
Dr. Arthur Gary Georgeu, D.M.D. Dentist - Periodontics Medicare: Medicare Enrolled Practice Location: 65 Newport Ave, Ste. 4, Rumford, RI 02916 Phone: 401-434-3220 Fax: 401-435-9350 |
Dr. Walter Raymond Shaghalian Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 1002 Pawtucket Ave, Rumford, RI 02916 Phone: 401-438-4964 Fax: 401-434-6021 |
News Archive
Children with peripherally inserted central catheters are more likely to develop blood clots, study shows
A study has found that children inserted with PICCs are at higher risk of developing blood clots called venous thromboembolism.
Prophylactic cranial irradiation prevents early lung cancer metastases to the brain
A national Radiation Therapy Oncology Group (RTOG) study led by a Medical College of Wisconsin Cancer Center physician at Froedtert Hospital in Milwaukee has found that a course of radiation therapy to the brain after treatment for locally advanced non-small cell lung cancer reduced the risk of metastases to the brain within the first year after treatment. The study was presented at the American Society of Clinical Oncology annual meeting in Orlando, June 1.
Canadian Rheumatology Association issues statement on Vioxx alternatives
The Canadian Rheumatology Association (CRA) has issued a statement to its 350 members and other interested parties, recommending alternative treatment considerations in the wake of the worldwide recall of Merck's rofecoxib, (Vioxx(R)) last week.
Experts discuss various aspects on health risks posed by fumigated containers
Common substances approved for fumigation, such as phosphine, usually evaporate within a short period of time. If used properly a risk to consumers is therefore unlikely according to current knowledge.
Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study
Genzyme Corporation announced today that a Phase 1/2 trial provided early clinical data suggesting that Mozobil (plerixafor injection) in combination with chemotherapy may offer a therapeutic impact on leukemic cells protected in bone marrow.
› Verified 8 days ago
Clinical Social Workers
Counselors
Pharmacists
Dentists
Occupational Therapists
Psychologists